02/28/2011 |
HHS/FDA |
Establishing a Baseline for Consumer Knowledge about Medical Product Benefits and Risks |
TERMS OF CLEARANCE
This generic IC is approved on the understanding that FDA plans to undertake more rigorous, quantitative analysis of the risk communications before releasing them to the public. FDA agrees to send a summary of results to OMB at the conclusion of this focus group study.
| File Type | application/msword |
| File Modified | 2010-04-09 |
| File Created | 2010-04-09 |